Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23866687 | 0.97 | CNR2 (0.31) | CNR2 | |
| SCHEMBL21398079 | 0.83 | LTB4R (0.32) | CNR2 | |
| SCHEMBL29308860 | 0.80 | NUDT1 (0.33) | NUDT1 | |
| SCHEMBL18523068 | 0.78 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL22930813 | 0.75 | NPC1 (0.39) | CNR2CNR1 | |
| SCHEMBL19363801 | 0.75 | TLR8 (0.32) | CNR2CNR1 | |
| SCHEMBL21398242 | 0.75 | NPC1 (0.39) | CNR2CNR1 | |
| SCHEMBL19363812 | 0.75 | TLR8 (0.32) | CNR2CNR1 | |
| SCHEMBL22930722 | 0.75 | MAPT (0.33) | CNR2CNR1 | |
| SCHEMBL21397906 | 0.75 | MAPT (0.33) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906894-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2021-02-02 | — | — | US | disclosed |
| US-20190292173-A1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292173-A1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | GPR119, GPR3, GPR39 | CNR2 40/4885NUDT1 1399/4885CNR1 69/4885 |
| US-10906894-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119 | GPR119, GPR3, GPR39 | CNR2 40/4885NUDT1 1399/4885CNR1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.